Drugging the undruggable RAS: Mission Possible?

被引:0
|
作者
Adrienne D. Cox
Stephen W. Fesik
Alec C. Kimmelman
Ji Luo
Channing J. Der
机构
[1] Lineberger Comprehensive Cancer Center,
[2] University of North Carolina at Chapel Hill,undefined
[3] Vanderbilt University School of Medicine,undefined
[4] Dana-Farber Cancer Institute,undefined
[5] National Cancer Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Attempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.
引用
收藏
页码:828 / 851
页数:23
相关论文
共 50 条
  • [11] Drugging the Undruggable: Small-molecule Inhibition of Ras Oncoprotein
    Fang, G.
    Maurer, T.
    Garrenton, L.
    Skelton, N.
    Fauber, B.
    Malek, S.
    Giannetti, A.
    Jackson, P.
    Rudolph, J.
    Wang, W.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 9 - 9
  • [12] Drugging the undruggable: Small-molecule inhibition of Ras oncoprotein
    Maurer, T.
    Garrenton, L. S.
    Oh, A.
    Pitts, K.
    Skelton, N. J.
    Fauber, B. P.
    Pan, B.
    Malek, S.
    Stokoe, D.
    Bowman, K. K.
    Wu, J.
    Giannetti, A. M.
    Starovasnik, M. A.
    Mellman, I.
    Jackson, P. K.
    Rudolph, J.
    Wang, W.
    Fang, G.
    CANCER RESEARCH, 2011, 71
  • [13] Drugging the Undruggable: Small-Molecule Inhibition of the Ras Oncoprotein
    Maurer, T.
    Garrenton, L.
    Oh, A.
    Pitts, K.
    Skelton, N.
    Fauber, B.
    Pan, B.
    Malek, S.
    Stokoe, D.
    Bowman, K.
    Wu, J.
    Giannetti, A.
    Starovasnik, M.
    Mellman, I.
    Jackson, P.
    Rudolph, J.
    Wang, W.
    Fang, G.
    MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [14] PHARMACEUTICALS Drugging the undruggable
    Jarvis, Lisa
    CHEMICAL & ENGINEERING NEWS, 2018, 96 (26) : 7 - 7
  • [15] Drugging the “undruggable” microRNAs
    Dejun Liu
    Xinqiang Wan
    Xiangxiang Shan
    Rengen Fan
    Wenzhang Zha
    Cellular and Molecular Life Sciences, 2021, 78 : 1861 - 1871
  • [16] Drugging "undruggable" targets
    Verdine, Gregory L.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3623S - 3623S
  • [17] Drugging the "undruggable" microRNAs
    Liu, Dejun
    Wan, Xinqiang
    Shan, Xiangxiang
    Fan, Rengen
    Zha, Wenzhang
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2021, 78 (05) : 1861 - 1871
  • [18] Drugging the 'undruggable' cancer targets
    Dang, Chi V.
    Reddy, E. Premkumar
    Shokat, Kevan M.
    Soucek, Laura
    NATURE REVIEWS CANCER, 2017, 17 (08) : 502 - 508
  • [19] RNAi Therapies: Drugging the Undruggable
    Wu, Sherry Y.
    Lopez-Berestein, Gabriel
    Calin, George A.
    Sood, Anil K.
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (240)
  • [20] Drugging an undruggable pocket on KRAS
    Kessler, Dirk
    Gmachl, Michael
    Mantoulidis, Andreas
    Martin, Laetitia J.
    Zoephel, Andreas
    Mayer, Moriz
    Gollner, Andreas
    Covini, David
    Fischer, Silke
    Gerstberger, Thomas
    Gmaschitz, Teresa
    Goodwin, Craig
    Greb, Peter
    Haring, Daniela
    Hela, Wolfgang
    Hoffmann, Johann
    Karolyi-Oezguer, Jale
    Knesi, Petr
    Kornigg, Stefan
    Koegl, Manfred
    Kousek, Roland
    Lamarre, Lyne
    Moser, Franziska
    Munico-Martinez, Silvia
    Peinsipp, Christoph
    Phan, Jason
    Rinnenthal, Joerg
    Sai, Jiqing
    Salamon, Christian
    Scherbantin, Yvonne
    Schipany, Katharina
    Schnitzer, Renate
    Schrenk, Andreas
    Sharps, Bernadette
    Siszler, Gabriella
    Sun, Qi
    Waterson, Alex
    Wolkerstorfer, Bernhard
    Zeeb, Markus
    Pearson, Mark
    Fesik, Stephen W.
    McConnell, Darryl B.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (32) : 15823 - 15829